Open AccessConcise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
Author(s) -
Jain Michael D.,
Davila Marco L.
Publication year - 2018
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.2715
Subject(s) - chimeric antigen receptor , clinical trial , cell therapy , cd19 , immunology , biology , genetic enhancement , lymphoma , antigen , immunotherapy , cancer research , stem cell , immune system , oncology , medicine , bioinformatics , gene , biochemistry , genetics
Abstract Gene‐engineered T cell therapies are soon to be United States Food and Drug Administration (FDA) approved for at least two types of B cell malignancies in pediatric and adult patients, in the form of CD19 targeted chimeric antigen receptor T (CAR T) cell therapy. This represents a triumph of a true bench to bedside clinical translation of a therapy that was conceived of in the early 1990s. Clinical results have demonstrated efficacious responses in patients with the CD19 positive diseases B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. However, significant challenges have emerged, including worrisome immune‐related toxicities, therapy resistance, and understanding how to administer CD19 CAR T cells in clinical practice. Although much remains to be learned, pioneering clinical trials have led to foundational insights about the clinical translation of this novel therapy. Here, we review the “lessons learned” from the pre‐clinical and human experience with CAR T cell therapy. S tem C ells 2018;36:36–44